Table 34:

Recommendations for vadadustat as an alternative to ESA in DD-CKD patients

Recommendation for use in research setting only	This recommendation is evidence informed.
Vadadustat should not be used for DD-CKD patients, except in the context of an approved randomized controlled trial. The panel recommends conducting large head-to-head multicentric randomized controlled trials in the South Asian region on DD-CKD patients and measuring critically important outcomes (as elucidated in this guideline) such that evidence base for vadadustat is improved.

DD: Dialysis-Dependent, CKD: Chronic kidney disease, ESA: Eythropoiesis-stimulating agents